

BPI INVEST GLOBAL HEALTH CARE FEEDER FUND

KEY INFORMATION AND INVESTMENT DISCLOSURE STATEMENT

As of August 31, 2022

Other Fees: 0.00%

FUND FACTS

Classification: Global Equity Feeder Fund

Launch Date: February 1, 2021

USD 1,000.00 **Minimum Investment:** Additional Investment: USD 500.00

Minimum Holding Period: None NAVPU: USD 83.04

Total Fund NAV (Mn): USD 6.68

Dealing Day: Daily up to 2:30 PM **Redemption Settlement:** T+5 End-of-Day

Early Redemption Charge:

None

FEES

Trustee Fees: 1.00%

As a percentage of average

daily NAV for the quarter

valued at USD 6.77 Million

BPI Asset Management

Custodianship Fee: 0.00%

None

External Audit Fee: 0.00%

Isla Lipana

None

To be determined upon receipt

of billing

INVESTMENT OBJECTIVE AND STRATEGY

The Fund, operating as a Feeder Fund, intends to achieve for its Participants long term capital growth by investing in a Target Fund that invests in stocks in the health care sector. The Fund aims to provide excess return over the MSCI World Health Care Index. Pursuant to existing BSP rules and regulations, as a Feeder Fund, this Fund is mandated to invest at least 90% of its assets in a single collective investment scheme.

CLIENT SUITABILITY

A client profiling process shall be performed prior to participating in the Fund to guide the prospective investor if the Fund is suited to his/her investment objectives and risk tolerance. Clients are advised to read the Declaration of Trust/Plan Rules of the Fund, which may be obtained from the Trustee, before deciding to invest.

The BPI Invest Global Health Care Feeder Fund is for investors who:

- Are at least classified as aggressive based on their risk profile.
- Have an investment horizon of at least five (5) years.

Participation in the Fund shall be open to Participants with legal capacity to contract and who are not considered US persons under the US securities and tax laws, subject to the other conditions, rules or provisions stated in the Plan Rules and those established by the Trustee. No beneficial owner shall hold more than 10% of the Fund. Any investor who owns more than 10% shall be asked to redeem the amount (or its equivalent number of units) in excess of 10% within thirty (30) calendar days.

KEY RISKS AND RISK MANAGEMENT

You should not invest in this Fund if you do not understand or are not comfortable with the accompanying risks.

Market/Price Risk:

Investors are exposed to adverse changes in the prices of global equities in the health care sector due to adverse market conditions, unfavorable company earnings and valuations, and negative developments in the political and economic conditions of the focus countries of the securities of the target fund.

Investors are exposed to the risk of loss due to the target fund's inability to convert security holdings to cash Liquidity Risk: immediately or in instances where conversion to cash is possible but at a highly disadvantageous price due to limited participants in the market, low trading volumes, market disruptions, among others.

Country Risk:

Investors are exposed to the risk of loss arising from negative developments in the political, economic and social conditions of the focus countries of the underlying securities of the target fund, which may adversely affect the value of the feeder fund.

FX Risk:

Investors are exposed to the risk of loss from a decline in the market value of the target fund when the market value of foreign currency denominated securities held by the target fund are translated to USD.

The Fund's investment outlets undergo proper screening and evaluation in accordance with the Trustee's accreditation process. The Fund may also use financial derivatives to hedge the portfolio against market and credit risks.

- THE UIT FUND IS NOT A DEPOSIT AND IS NOT INSURED BY THE PHILIPPINE DEPOSIT INSURANCE CORP. (PDIC).
- RETURNS CANNOT BE GUARANTEED AND HISTORICAL NAVPU IS FOR ILLUSTRATION OF NAVPU MOVEMENTS/ FLUCTUATIONS ONLY.
- WHEN REDEEMING, THE PROCEEDS MAY BE WORTH LESS THAN THE ORIGINAL INVESTMENT AND ANY LOSSES SHALL BE SOLELY FOR THE ACCOUNT OF THE CLIENT.
- THE TRUSTEE IS NOT LIABLE FOR ANY LOSS UNLESS UPON WILLFUL DEFAULT, BAD FAITH OR GROSS **NEGLIGENCE.**

For more information, you may contact us at (632) 8580-AMTC (2682), email us at bpi_asset_management@bpi.com.ph or visit our website, www.bpiassetmanagement.com.

FUND PERFORMANCE AND STATISTICS AS OF August 31, 2022 (Purely for reference purposes and is not a guarantee of future results) **NAVPU GRAPH** NAVPu over the past 12 months 120 **Highest** 104.45 110 Lowest 76.96 100 **STATISTICS** 90 Volatility, since inception (%) 4 18.50 80 Sharpe Ratio 5 -1.07 Information Ratio 6 -0.43Feb-21 Mar-21 May-21 Jul-21 Aug-21 Oct-21 Nov-21 Jan-22 Mar-22 Apr-22 Jun-22 Aug-22 *MSCI World Health Care Index ¹ Returns are net of fees. CUMULATIVE PERFORMANCE (%) 1 ² Since Inception S.I.² 1 mo 3 mos 6 mos 1YR 3YRS ³ Fund performance from Feb to year-end 2021 Fund -18.98 -5.06 -0.79 -6.68 -16.96 ⁴ Measures the degree to which the Fund fluctuates vis-à-Benchmark 2.81 -6.02-6.03 -5.61 -11.02 vis its average return over a period of time ANNUALIZED PERFORMANCE (%) 1 ⁵ Used to characterize how well the return of a Fund S.I.² 1YR 2YRS 3YRS 4YRS 5YR compensates the investor for the level of risk taken. The -11.11 Fund -18.98 higher the number, the better. Benchmark 1.77 -11.02 ⁶ Measures reward-to-risk efficiency of the portfolio CALENDAR YEAR PERFORMANCE (%) 1 relative to the benchmark. The higher the number, the higher the reward per unit of risk. YTD 2021³ *Declaration of Trust is available upon request through Fund -16.24 -0.86 your branch of account. Benchmark -12.97 18.13 PORTFOLIO COMPOSITION Allocation % of Fund 98.25 Target Fund **TOP TEN HOLDINGS** Cash and Equivalents 1.93 Name % of Target Fund Others – net of liabilities -0.19 UnitedHealth Grp Inc 8.41 Regional Breakdown % of Target Fund **United States** 73.54 Eli Lilly & Co 6.08 United Kingdom 8.35 5.23 AstraZeneca PLC Switzerland 5.29 Pfizer Inc 5.02 Others 12.82 4.17 Danaher Corp % of Target Fund Sector Breakdown Novartis AG 3.89 Major Pharmaceuticals 25.03 Bristol-Myers Squibb 3.21 Biotechnology 17.65 3.07 Humana Inc **Health Services** 17.43 Medical Technology 14.70 Daiichi Sankyo Co 2.74 Others 25.19 Vertex Pharm Inc 2.66 **RELATED PARTY TRANSACTIONS***

Regulator:

The Fund has no transactions and outstanding investments with entities related to BPI Asset Management and Trust Corporation (BPI AMTC).

* Related party in accordance with BPI AMTC's internal policy.

OTHER FUND FACTS

Fund Currency: US Dollar Benchmark*: MSCI World Health Care Index

Wellington Global Health Care Equity Name of Target Fund:

Fund

Inception Date:

Fund structure: UCITS (IRL) October 31, 2003

State Street Custodial Services

Custodian: (Ireland) Limited

Total Expense Ratio: 1.32%

Fund Manager: Wellington Management Company LLP

Central Bank of Ireland

The Fund Performance Report and relevant information about the Wellington Global Health Care Equity Fund can be viewed and downloaded through https://www.wellingtonfunds.com/en-at/institutional/.

OUTLOOK AND STRATEGY

Market Review. Global equity markets declined in August as the global economy continued to face the effects of high inflation. Markets started the month on a positive note as investors priced in a slowing Fed hiking cycle due to below-expectations US inflation print. Later in the month, markets detracted after global central banks, including the Federal Reserve and the European Central Bank, signaled more monetary tightening policies. MSCI World Health Care returned -6.0% for the month, with biopharma small-cap and health care services as the best-performing sectors over the period

Fund Performance. The fund returned -5.06% in August, outperforming the benchmark by 96 basis points. Sector allocation in biopharma small-cap helped performance.

Fund Strategy. Current market valuations, strong fundamentals and robust innovation pipeline leaves us with a more positive outlook for the health care sector. Attractive valuations and breakthrough innovations in the biopharma industry, particularly in oncology and certain rare diseases, are compelling and are creating a rich opportunity set for investors. Outside of biopharma, medical technology companies have numerous opportunities as more attractive medical device categories are poised to accelerate compared to a decade ago, such as new diabetes devices, genetic sequencing and diagnostics. In the medium-term, many firms are expected to grow their addressable market through geographic expansion, new technologies, and new patient populations. The fund will continue to favor companies that develop innovative products designed to address important unmet medical needs. Over the long term, the tailwinds of innovation, an aging population and the globalization of demand cuttingedge Western-style medicines should continue to drive growth for the sector.

LIST OF PROSPECTIVE INVESTMENTS

The following are among the Fund's approved investment outlets, wherein the Trustee intends to invest depending on strategy, availability, or other market-driven circumstances:

- (a) Primarily in a single collective investment scheme whose investment objective is to provide investment results in excess of the return of the MSCI World Health Care Index; provided further that such CIS is approved or registered and supervised by a regulatory authority that is a member of the International Organization of Securities Commissions (IOSCO) and managed by reputable fund manager/s; provided further that the investment in the said collective investment scheme should at least be ninety percent (90%) of the total assets of the Fund. The Target Fund must be recognized as a collective investment scheme in its home jurisdiction by a regulatory authority or any regulatory authority acceptable to the BSP to supervise this CIS.
- (b) Short-term tradable fixed-income instruments issued or guaranteed by the Philippine government or the BSP; tradable securities issued by the government of a foreign country, any political subdivision/agency of a foreign country or any supranational entity; tradable fixed-income instruments issued by foreign or local financial institutions or private corporations; exchange- listed securities; marketable instruments that are traded in an organized exchange; loans traded in an organized market; and, such other tradable investments outlets/ categories as the BSP may allow. Provided, that, a financial instrument is regarded as tradable if two-way prices are quoted, readily available or regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis.
- (c) Short-term tradable fixed-income instruments issued, underwritten, or otherwise dealt by BPI and/or any of its subsidiaries, affiliates, their successors-in-interest or assignees, their directors, officers, stockholders, and related interest, and any of their trust and fund managed accounts, under such terms and conditions as the Trustee may deem to be in the best interest of the Fund; and, any such other instruments as may be allowed under BSP regulations. Investment with related interests shall be in accordance with Section 414-Q of the Manual of Regulations for Non-Bank Financial Institutions.
- (d) The principal investments of the Fund will be denominated in, but not limited to the U.S. Dollar. The target fund invests in securities denominated in other currencies.
- (e) Bank deposits or tradable debt instruments issued by the BSP.
- (f) Such other investments allowed under regulations issued by the BSP.

INVESTMENT OBJECTIVE OF TARGET FUND

The Wellington Global Health Care Equity Fund seeks long-term total returns. The Investment Manager will actively manage the Fund, seeking to achieve the objective by investing in the equity securities of health care companies worldwide. The Fund takes a long term value approach and seeks to invest in fundamentally sound companies. Although the Fund is not constructed relative to a benchmark, the MSCI World Health Care index will serve as a reference benchmark.

BPI Asset Management and Trust Corporation (BPI AMTC) is a subsidiary of the Bank of the Philippine Islands. For inquiries and comments, please send an email to bpi_asset_management@bpi.com.ph or call us at (02) 8580-AMTC (2682). Regulated by the Bangko Sentral ng Pilipinas. https://www.bsp.gov.ph, BSP Webchat https://www.bsp.gov.ph SMS: 021582277 & BSP CAMS Facebook https://www.facebook.com/BangkoSentralngPilipinas